Who are midazolam,fentanyl,etomidate,Cisatracurium besylate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/midazolam-fentanyl-etomidate-cisatracurium-besylate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

midazolam,fentanyl,etomidate,Cisatracurium besylate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

midazolam,fentanyl,etomidate,Cisatracurium besylate (midazolam,fentanyl,etomidate,Cisatracurium besylate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anesthetic combination (benzodiazepine, opioid, hypnotic, neuromuscular blocker). Area: Anesthesiology.

marketed Anesthetic combination (benzodiazepine, opioid, hypnotic, neuromuscular blocker) GABA-A receptor (midazolam, etomidate), mu opioid receptor (fentanyl), nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium) Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

midazolam,fentanyl,etomidate,Cisatracurium besylate (midazolam,fentanyl,etomidate,Cisatracurium besylate) — First Affiliated Hospital Xi'an Jiaotong University. This is a combination of four anesthetic and neuromuscular blocking agents used together for induction and maintenance of general anesthesia with paralysis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
midazolam,fentanyl,etomidate,Cisatracurium besylate TARGET	midazolam,fentanyl,etomidate,Cisatracurium besylate	First Affiliated Hospital Xi'an Jiaotong University	marketed	Anesthetic combination (benzodiazepine, opioid, hypnotic, neuromuscular blocker)	GABA-A receptor (midazolam, etomidate), mu opioid receptor (fentanyl), nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anesthetic combination (benzodiazepine, opioid, hypnotic, neuromuscular blocker) class)

First Affiliated Hospital Xi'an Jiaotong University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). midazolam,fentanyl,etomidate,Cisatracurium besylate — Competitive Intelligence Brief. https://druglandscape.com/ci/midazolam-fentanyl-etomidate-cisatracurium-besylate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab